An UPLC–MS/MS method for separation and accurate quantification of tamoxifen and its metabolites isomers-Reference-Cited by-同舟云学术

An UPLC–MS/MS method for separation and accurate quantification of tamoxifen and its metabolites isomers

Published:2014-11 Issue: Volume:100 Page:254-261
ISSN:0731-7085
Container-title:Journal of Pharmaceutical and Biomedical Analysis
language:en
Short-container-title:Journal of Pharmaceutical and Biomedical Analysis

Author:

Arellano Cécile,Allal Ben,Goubaa Anwar^ORCID,Roché Henri,Chatelut Etienne

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry

Reference29 articles.

1. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen;Johnson;Breast Cancer Res. Treat.,2004

2. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine;Stearns;J. Natl. Cancer Inst.,2003

3. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells;Katzenellenbogen;Cancer Res.,1984

4. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen;Lim;Cancer Chemother. Pharmacol.,2005

5. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen;Goetz;Breast Cancer Res. Treat.,2007

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. THE APPLICATION OF BIOANALYTICAL METHOD OF TAMOXIFEN AND ITS ACTIVE METABOLITES FOR THERAPEUTIC DRUG MONITORING IN BREAST CANCER PATIENTS: A REVIEW;International Journal of Applied Pharmaceutics;2024-05-07

2. Development and validation of a liquid chromatography-mass spectrometry assay for quantification of Z- and E- isomers of endoxifen and its metabolites in plasma from women with estrogen receptor positive breast cancer;Journal of Chromatography B;2023-04

3. Model‐Based Quantification of Impact of Genetic Polymorphisms and Co‐Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer;Clinical Pharmacology & Therapeutics;2020-11-10

4. Development and validation of UPLC-MS/MS method for studying the pharmacokinetic interaction of dasabuvir and tamoxifen, 4-hydroxytamoxifen in Wistar rats;Scientific Reports;2020-02-26

5. CYP2D6 Genotype–Guided Tamoxifen Dosing in Hormone Receptor–Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study;Journal of Clinical Oncology;2020-02-20